| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interleukin-2 | 30 | 2023 | 87 | 4.590 |
Why?
|
| STAT5 Transcription Factor | 29 | 2023 | 44 | 4.050 |
Why?
|
| Protein-Tyrosine Kinases | 28 | 2021 | 121 | 3.530 |
Why?
|
| Signal Transduction | 38 | 2023 | 1802 | 3.270 |
Why?
|
| T-Lymphocytes | 30 | 2013 | 341 | 2.930 |
Why?
|
| Cytokines | 14 | 2021 | 569 | 2.250 |
Why?
|
| Janus Kinase 3 | 26 | 2023 | 33 | 2.110 |
Why?
|
| Trans-Activators | 22 | 2004 | 167 | 1.930 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 37 | 1.910 |
Why?
|
| Phosphorylation | 36 | 2023 | 878 | 1.740 |
Why?
|
| Milk Proteins | 14 | 2003 | 28 | 1.710 |
Why?
|
| MAP Kinase Signaling System | 5 | 2021 | 162 | 1.610 |
Why?
|
| Immunosuppressive Agents | 15 | 2005 | 72 | 1.430 |
Why?
|
| DNA-Binding Proteins | 21 | 2004 | 522 | 1.310 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2021 | 180 | 1.270 |
Why?
|
| Mutation | 5 | 2023 | 1023 | 1.260 |
Why?
|
| Janus Kinases | 5 | 2023 | 19 | 1.260 |
Why?
|
| Receptors, Interleukin-2 | 12 | 2009 | 29 | 1.240 |
Why?
|
| Heart Transplantation | 12 | 2006 | 43 | 1.210 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 3 | 2018 | 6 | 1.170 |
Why?
|
| Graft Survival | 7 | 2005 | 34 | 1.160 |
Why?
|
| Graft Rejection | 10 | 2006 | 38 | 1.150 |
Why?
|
| Lymphocytes | 5 | 2019 | 116 | 1.040 |
Why?
|
| Cell Proliferation | 5 | 2022 | 1149 | 1.020 |
Why?
|
| Lymphoma | 4 | 2013 | 37 | 1.020 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2021 | 229 | 0.960 |
Why?
|
| Tyrosine | 16 | 2023 | 109 | 0.950 |
Why?
|
| Lymphocyte Activation | 13 | 2007 | 222 | 0.950 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2021 | 57 | 0.920 |
Why?
|
| Cell Line | 25 | 2021 | 1289 | 0.900 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2023 | 162 | 0.890 |
Why?
|
| Phosphoserine | 2 | 2021 | 18 | 0.880 |
Why?
|
| MAP Kinase Kinase 3 | 1 | 2021 | 3 | 0.850 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2021 | 6 | 0.830 |
Why?
|
| STAT Transcription Factors | 3 | 2021 | 10 | 0.810 |
Why?
|
| Humans | 69 | 2023 | 34853 | 0.790 |
Why?
|
| Neoplasm Proteins | 2 | 2022 | 203 | 0.770 |
Why?
|
| Mannich Bases | 3 | 2010 | 4 | 0.750 |
Why?
|
| STAT3 Transcription Factor | 6 | 2008 | 80 | 0.730 |
Why?
|
| Apoptosis | 10 | 2019 | 1317 | 0.720 |
Why?
|
| Enzyme Activation | 17 | 2022 | 423 | 0.710 |
Why?
|
| Enzyme Inhibitors | 10 | 2002 | 396 | 0.690 |
Why?
|
| Isoproterenol | 1 | 2018 | 35 | 0.670 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 17 | 0.670 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 15 | 0.660 |
Why?
|
| Phosphotyrosine | 8 | 2021 | 24 | 0.660 |
Why?
|
| Serine | 10 | 2015 | 72 | 0.660 |
Why?
|
| Transplantation, Homologous | 12 | 2006 | 35 | 0.630 |
Why?
|
| Amino Acid Sequence | 14 | 2021 | 1124 | 0.600 |
Why?
|
| Cell Survival | 11 | 2016 | 818 | 0.600 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2016 | 9 | 0.580 |
Why?
|
| Pyridazines | 1 | 2016 | 14 | 0.580 |
Why?
|
| Cell Line, Tumor | 12 | 2022 | 2128 | 0.580 |
Why?
|
| Tyrphostins | 6 | 2001 | 14 | 0.570 |
Why?
|
| Interleukin-4 | 9 | 2004 | 69 | 0.560 |
Why?
|
| Imidazoles | 1 | 2016 | 124 | 0.550 |
Why?
|
| Threonine | 1 | 2015 | 21 | 0.540 |
Why?
|
| Prolactin | 10 | 2007 | 59 | 0.530 |
Why?
|
| Immune Tolerance | 5 | 2008 | 61 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2022 | 781 | 0.510 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 209 | 0.500 |
Why?
|
| Sirolimus | 5 | 2004 | 58 | 0.500 |
Why?
|
| Janus Kinase 1 | 7 | 2023 | 17 | 0.490 |
Why?
|
| Animals | 47 | 2023 | 14307 | 0.480 |
Why?
|
| Prodigiosin | 3 | 2002 | 3 | 0.480 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 9 | 0.460 |
Why?
|
| Cell Nucleus | 4 | 2012 | 351 | 0.460 |
Why?
|
| Pyrroles | 3 | 2002 | 54 | 0.460 |
Why?
|
| Enzyme Assays | 1 | 2013 | 11 | 0.460 |
Why?
|
| Phosphoproteins | 3 | 2007 | 154 | 0.430 |
Why?
|
| Homeostasis | 3 | 2008 | 172 | 0.430 |
Why?
|
| Molecular Sequence Data | 14 | 2015 | 1490 | 0.430 |
Why?
|
| Protein Phosphatase 2 | 2 | 2009 | 22 | 0.430 |
Why?
|
| Cyclic AMP | 1 | 2013 | 125 | 0.430 |
Why?
|
| Repressor Proteins | 2 | 2019 | 226 | 0.420 |
Why?
|
| Tumor Suppressor Proteins | 10 | 2009 | 184 | 0.410 |
Why?
|
| Blotting, Western | 6 | 2016 | 834 | 0.400 |
Why?
|
| NF-kappa B | 3 | 2009 | 306 | 0.390 |
Why?
|
| Monocytes | 1 | 2013 | 258 | 0.390 |
Why?
|
| Protein Kinases | 3 | 2003 | 91 | 0.370 |
Why?
|
| Cyclosporine | 5 | 2005 | 26 | 0.360 |
Why?
|
| Hep G2 Cells | 2 | 2021 | 52 | 0.350 |
Why?
|
| Transplantation Tolerance | 2 | 2006 | 3 | 0.350 |
Why?
|
| Leukemia | 2 | 2023 | 54 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2019 | 245 | 0.340 |
Why?
|
| Transcription Factors | 4 | 2002 | 653 | 0.330 |
Why?
|
| B-Lymphocytes | 3 | 2006 | 181 | 0.330 |
Why?
|
| Rats, Inbred ACI | 8 | 2005 | 10 | 0.320 |
Why?
|
| src-Family Kinases | 2 | 2019 | 42 | 0.320 |
Why?
|
| Cells, Cultured | 11 | 2009 | 1442 | 0.310 |
Why?
|
| Protein Binding | 5 | 2013 | 913 | 0.310 |
Why?
|
| Rats | 19 | 2005 | 3261 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 178 | 0.300 |
Why?
|
| Mice | 25 | 2023 | 5668 | 0.290 |
Why?
|
| Hordeum | 2 | 2019 | 13 | 0.290 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2006 | 26 | 0.290 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 2013 | 195 | 0.260 |
Why?
|
| Interleukin-9 | 4 | 2008 | 6 | 0.260 |
Why?
|
| Interleukin-13 | 4 | 2004 | 18 | 0.260 |
Why?
|
| Janus Kinase 2 | 8 | 2023 | 31 | 0.250 |
Why?
|
| Temperature | 2 | 2018 | 275 | 0.250 |
Why?
|
| Mitochondrial Membranes | 2 | 2019 | 38 | 0.250 |
Why?
|
| Rats, Inbred Lew | 6 | 2005 | 21 | 0.250 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 4 | 2009 | 17 | 0.250 |
Why?
|
| Transcriptional Activation | 2 | 2004 | 164 | 0.250 |
Why?
|
| Mitochondria | 1 | 2007 | 454 | 0.240 |
Why?
|
| Receptors, Interleukin | 4 | 2000 | 10 | 0.240 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 19 | 0.240 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2018 | 90 | 0.240 |
Why?
|
| Immunoprecipitation | 3 | 2013 | 126 | 0.220 |
Why?
|
| Cell Division | 9 | 2001 | 296 | 0.220 |
Why?
|
| Protein Phosphatase 1 | 2 | 2015 | 58 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 12 | 2008 | 480 | 0.210 |
Why?
|
| Drug Synergism | 3 | 2016 | 171 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2022 | 80 | 0.200 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2001 | 1 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 282 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 391 | 0.200 |
Why?
|
| Antibodies | 1 | 2021 | 135 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 984 | 0.200 |
Why?
|
| Gene Expression Regulation | 5 | 2015 | 968 | 0.200 |
Why?
|
| Transplantation Immunology | 3 | 2008 | 5 | 0.200 |
Why?
|
| Cell Transformation, Viral | 1 | 2000 | 29 | 0.200 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2000 | 33 | 0.200 |
Why?
|
| Jurkat Cells | 3 | 2007 | 72 | 0.190 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 18 | 0.190 |
Why?
|
| Hydrogen Peroxide | 2 | 2019 | 181 | 0.190 |
Why?
|
| Mexico | 1 | 2021 | 223 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2022 | 600 | 0.180 |
Why?
|
| Genomics | 1 | 2021 | 201 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 605 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 3 | 2009 | 484 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2000 | 166 | 0.180 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 4 | 2013 | 430 | 0.170 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1998 | 1 | 0.170 |
Why?
|
| Peptides | 1 | 2021 | 308 | 0.170 |
Why?
|
| Plant Extracts | 2 | 2019 | 250 | 0.170 |
Why?
|
| Benzidines | 1 | 2018 | 8 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Colorimetry | 1 | 2018 | 40 | 0.160 |
Why?
|
| Immunoassay | 1 | 2018 | 57 | 0.160 |
Why?
|
| Polyenes | 1 | 1997 | 4 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2002 | 116 | 0.160 |
Why?
|
| Androstadienes | 1 | 1997 | 18 | 0.160 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2008 | 168 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 2018 | 95 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2017 | 70 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2017 | 19 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 52 | 0.150 |
Why?
|
| Flavonoids | 1 | 1997 | 78 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2012 | 224 | 0.150 |
Why?
|
| K562 Cells | 1 | 2016 | 31 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 19 | 0.150 |
Why?
|
| Protein Conformation | 2 | 2008 | 350 | 0.150 |
Why?
|
| STAT6 Transcription Factor | 6 | 2004 | 16 | 0.140 |
Why?
|
| Bacillus | 1 | 1995 | 8 | 0.140 |
Why?
|
| Immunoblotting | 4 | 2013 | 170 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 117 | 0.140 |
Why?
|
| Electron Transport Complex IV | 1 | 1995 | 35 | 0.140 |
Why?
|
| Receptors, Erythropoietin | 2 | 2000 | 7 | 0.140 |
Why?
|
| Rats, Inbred WF | 4 | 2002 | 4 | 0.130 |
Why?
|
| Receptors, Prolactin | 4 | 1996 | 13 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2008 | 38 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 97 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 94 | 0.130 |
Why?
|
| Cell Cycle | 3 | 2022 | 309 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 1995 | 140 | 0.130 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2012 | 54 | 0.130 |
Why?
|
| Phosphoamino Acids | 2 | 2013 | 3 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2007 | 897 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 371 | 0.120 |
Why?
|
| Kinetics | 4 | 2003 | 650 | 0.120 |
Why?
|
| Kidney Transplantation | 2 | 2005 | 85 | 0.120 |
Why?
|
| Leukocytes | 1 | 1994 | 68 | 0.120 |
Why?
|
| Minority Groups | 1 | 2019 | 537 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2018 | 294 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2019 | 874 | 0.120 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2013 | 13 | 0.120 |
Why?
|
| Phytohemagglutinins | 2 | 2004 | 12 | 0.110 |
Why?
|
| Protein Subunits | 1 | 2013 | 85 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2013 | 100 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 70 | 0.110 |
Why?
|
| Caspases | 2 | 2022 | 132 | 0.110 |
Why?
|
| Gene Expression | 3 | 2013 | 639 | 0.110 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 220 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 107 | 0.110 |
Why?
|
| DNA | 4 | 2004 | 549 | 0.110 |
Why?
|
| Interleukin-15 | 2 | 2002 | 13 | 0.110 |
Why?
|
| Protein Transport | 1 | 2013 | 286 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2002 | 20 | 0.100 |
Why?
|
| Th2 Cells | 3 | 2000 | 56 | 0.100 |
Why?
|
| Sequence Alignment | 3 | 2008 | 257 | 0.100 |
Why?
|
| Proline | 2 | 2002 | 37 | 0.100 |
Why?
|
| Transfection | 6 | 2003 | 496 | 0.100 |
Why?
|
| Genomic Library | 1 | 2009 | 7 | 0.090 |
Why?
|
| Receptors, Cytokine | 2 | 2000 | 11 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2009 | 48 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 485 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 52 | 0.090 |
Why?
|
| Amino Acid Substitution | 2 | 2008 | 122 | 0.090 |
Why?
|
| Interleukin-7 | 2 | 2002 | 7 | 0.090 |
Why?
|
| Response Elements | 1 | 2009 | 52 | 0.090 |
Why?
|
| Binding Sites | 2 | 2009 | 597 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2009 | 71 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2022 | 107 | 0.090 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 794 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2008 | 249 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 40 | 0.090 |
Why?
|
| Adenosine Triphosphate | 2 | 2008 | 180 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 550 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2022 | 72 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 16 | 0.080 |
Why?
|
| Rats, Inbred BN | 3 | 2002 | 19 | 0.080 |
Why?
|
| Neoplasms | 2 | 2008 | 1033 | 0.080 |
Why?
|
| Cell Movement | 2 | 2022 | 545 | 0.080 |
Why?
|
| Models, Biological | 2 | 2004 | 642 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2008 | 106 | 0.080 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 79 | 0.080 |
Why?
|
| Disease Progression | 1 | 2010 | 580 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2008 | 186 | 0.080 |
Why?
|
| Spleen | 2 | 2005 | 192 | 0.080 |
Why?
|
| Oxidation-Reduction | 3 | 2018 | 407 | 0.080 |
Why?
|
| Receptors, Androgen | 1 | 2008 | 122 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2007 | 59 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2004 | 376 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 19 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 255 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2007 | 562 | 0.070 |
Why?
|
| Cell Line, Transformed | 2 | 2007 | 87 | 0.070 |
Why?
|
| Proteomics | 1 | 2007 | 302 | 0.070 |
Why?
|
| Carcinoma | 1 | 2006 | 94 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 490 | 0.070 |
Why?
|
| Selectins | 1 | 2004 | 1 | 0.070 |
Why?
|
| Hexanes | 1 | 2004 | 2 | 0.070 |
Why?
|
| Male | 9 | 2019 | 18870 | 0.060 |
Why?
|
| Mannose | 1 | 2004 | 25 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 310 | 0.060 |
Why?
|
| Caseins | 2 | 2001 | 13 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 4 | 2017 | 649 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2008 | 751 | 0.060 |
Why?
|
| Chemokines | 1 | 2004 | 89 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2001 | 175 | 0.060 |
Why?
|
| Molecular Weight | 2 | 1994 | 161 | 0.060 |
Why?
|
| Enzyme Precursors | 1 | 2003 | 10 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 42 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2003 | 27 | 0.060 |
Why?
|
| Receptors, Interferon | 1 | 2023 | 14 | 0.060 |
Why?
|
| Base Sequence | 7 | 2001 | 932 | 0.060 |
Why?
|
| Caspase 8 | 1 | 2003 | 31 | 0.060 |
Why?
|
| Growth Inhibitors | 2 | 2000 | 23 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 286 | 0.060 |
Why?
|
| RNA, Messenger | 4 | 2001 | 1152 | 0.060 |
Why?
|
| Proto-Oncogene Proteins A-raf | 1 | 2002 | 1 | 0.060 |
Why?
|
| Phorbol Esters | 1 | 2002 | 8 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 10 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2000 | 52 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 85 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2002 | 23 | 0.050 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2002 | 3 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 7 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2002 | 6 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2002 | 12 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 24 | 0.050 |
Why?
|
| Rats, Inbred BUF | 1 | 2002 | 1 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2002 | 121 | 0.050 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 9 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 322 | 0.050 |
Why?
|
| Phosphatidylserines | 1 | 2022 | 19 | 0.050 |
Why?
|
| Interleukins | 1 | 2002 | 28 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2001 | 20 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 36 | 0.050 |
Why?
|
| Exocytosis | 1 | 2022 | 45 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2001 | 30 | 0.050 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2022 | 71 | 0.050 |
Why?
|
| Mammary Glands, Animal | 1 | 2001 | 25 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 137 | 0.050 |
Why?
|
| Tubulin | 1 | 2022 | 80 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 212 | 0.050 |
Why?
|
| Calcineurin | 1 | 2001 | 21 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 58 | 0.050 |
Why?
|
| Biopolymers | 1 | 2000 | 17 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2000 | 37 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 200 | 0.050 |
Why?
|
| Ubiquitins | 1 | 2000 | 45 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 247 | 0.050 |
Why?
|
| Microtubules | 1 | 2022 | 113 | 0.050 |
Why?
|
| Cell Death | 1 | 2022 | 260 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2000 | 57 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2000 | 63 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 114 | 0.050 |
Why?
|
| Receptors, Interleukin-4 | 2 | 1996 | 10 | 0.050 |
Why?
|
| Hospitalization | 1 | 2023 | 370 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 416 | 0.040 |
Why?
|
| Cytochromes c | 1 | 2019 | 45 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1999 | 14 | 0.040 |
Why?
|
| Antigens | 1 | 1999 | 56 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 29 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 65 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 287 | 0.040 |
Why?
|
| Photochemical Processes | 1 | 2018 | 17 | 0.040 |
Why?
|
| Phenols | 1 | 2019 | 76 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1530 | 0.040 |
Why?
|
| Sulfhydryl Reagents | 1 | 1998 | 6 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 707 | 0.040 |
Why?
|
| Hela Cells | 1 | 2019 | 344 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2000 | 251 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 1998 | 86 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1998 | 122 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 964 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 1997 | 21 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 1997 | 36 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 1998 | 86 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1996 | 8 | 0.040 |
Why?
|
| Proteins | 2 | 1999 | 352 | 0.040 |
Why?
|
| Time Factors | 3 | 1998 | 1681 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 1426 | 0.040 |
Why?
|
| Cell Membrane | 2 | 1995 | 360 | 0.040 |
Why?
|
| Phagocytosis | 1 | 1996 | 64 | 0.030 |
Why?
|
| Mitogens | 1 | 1995 | 10 | 0.030 |
Why?
|
| Cytochrome c Group | 1 | 1995 | 13 | 0.030 |
Why?
|
| Industrial Microbiology | 1 | 1995 | 5 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1995 | 11 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 51 | 0.030 |
Why?
|
| Genes, ras | 1 | 1995 | 22 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1998 | 287 | 0.030 |
Why?
|
| Neutrophils | 1 | 1996 | 124 | 0.030 |
Why?
|
| Heme | 1 | 1995 | 69 | 0.030 |
Why?
|
| Catalysis | 1 | 1995 | 162 | 0.030 |
Why?
|
| Isoelectric Point | 1 | 1994 | 9 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1994 | 25 | 0.030 |
Why?
|
| Female | 4 | 2022 | 19873 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 19 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 1995 | 486 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1996 | 298 | 0.030 |
Why?
|
| Adoptive Transfer | 2 | 2006 | 48 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2013 | 91 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 194 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 583 | 0.030 |
Why?
|
| Ligands | 1 | 1994 | 317 | 0.030 |
Why?
|
| Clone Cells | 2 | 2001 | 46 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2001 | 83 | 0.030 |
Why?
|
| Sheep | 3 | 1996 | 70 | 0.020 |
Why?
|
| United States | 1 | 2019 | 3894 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 1998 | 51 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 2 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 21 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 23 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 59 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 35 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 1998 | 132 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 2 | 1999 | 26 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 57 | 0.020 |
Why?
|
| Androgens | 1 | 2008 | 87 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 242 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 323 | 0.020 |
Why?
|
| G1 Phase | 1 | 2006 | 32 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 445 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 126 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2006 | 81 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 1996 | 87 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2004 | 132 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 298 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 232 | 0.020 |
Why?
|
| Mutagenesis | 2 | 1995 | 87 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 53 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 608 | 0.020 |
Why?
|
| HIV Infections | 1 | 1998 | 2207 | 0.020 |
Why?
|
| Plasmids | 2 | 1995 | 233 | 0.010 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 3 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 40 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2001 | 21 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2001 | 31 | 0.010 |
Why?
|
| Lactation | 1 | 2001 | 38 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 217 | 0.010 |
Why?
|
| Receptors, Interleukin-9 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Polyubiquitin | 1 | 2000 | 6 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2000 | 61 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2000 | 78 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 472 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2000 | 109 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1999 | 2 | 0.010 |
Why?
|
| Alanine | 1 | 1998 | 28 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 62 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1998 | 23 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 139 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1998 | 22 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1998 | 41 | 0.010 |
Why?
|
| Iodobenzoates | 1 | 1998 | 2 | 0.010 |
Why?
|
| Spodoptera | 1 | 1998 | 11 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 1998 | 74 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1998 | 12 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1998 | 18 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 73 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 310 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 123 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1997 | 22 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1997 | 87 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 235 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 455 | 0.010 |
Why?
|
| Kanamycin Kinase | 1 | 1996 | 2 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 283 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 1503 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 21 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 30 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1996 | 48 | 0.010 |
Why?
|
| Son of Sevenless Proteins | 1 | 1995 | 2 | 0.010 |
Why?
|
| GRB2 Adaptor Protein | 1 | 1995 | 7 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1998 | 420 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1995 | 26 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1994 | 12 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1994 | 2 | 0.010 |
Why?
|
| Ornithine Decarboxylase | 1 | 1994 | 10 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 278 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1994 | 42 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1994 | 31 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 84 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1994 | 9 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1995 | 156 | 0.010 |
Why?
|
| Autoradiography | 1 | 1994 | 36 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 239 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 269 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1994 | 392 | 0.010 |
Why?
|